Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s

 
• By Jessica Merrill
  
go big
Merck & Co. is planning a big Phase III program for its oral PCSK9 inhibitor • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

More from Therapy Areas